The History and Future of Chemotherapy for Melanoma

Por Yang, Arvin S., Chapman, Paul B.
Publicado em 2009

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

Por Iasonos, Alexia, Chapman, Paul B., Satagopan, Jaya M.
Publicado no Clin Cancer Res (2016)

Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells

Por Wu, Dianna Y., Segal, Neil H., Sidobre, Stephane, Kronenberg, Mitchell, Chapman, Paul B.
Publicado em 2003

Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines

Por Romano, Emanuela, Scordo, Michael, Dusza, Stephen W., Coit, Daniel G., Chapman, Paul B.
Publicado em 2010

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma

Por Polsky David, Osman Iman, Panageas Katherine S, Chang David Z, Busam Klaus, Chapman Paul B
Publicado em 2004-12-01

Clinical significance of BRAF mutations in metastatic melanoma

Por Chang, David Z, Panageas, Katherine S, Osman, Iman, Polsky, David, Busam, Klaus, Chapman, Paul B
Publicado em 2004

Opportunistic infections in patients treated with immunotherapy for cancer

Por Kyi, Chrisann, Hellmann, Matthew D, Wolchok, Jedd D, Chapman, Paul B, Postow, Michael A
Publicado em 2014

Safety of Infusing Ipilimumab Over 30 Minutes

Por Momtaz, Parisa, Park, Vivian, Panageas, Katherine S., Postow, Michael A., Callahan, Margaret, Wolchok, Jedd D., Chapman, Paul B.
Publicado no J Clin Oncol (2015)

Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand

Por Park, Jun-Eui, Wu, Dianna Y, Prendes, Maria, Lu, Sharon X, Ragupathi, Govind, Schrantz, Nicolas, Chapman, Paul B
Publicado em 2008

Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy

Por Harding, James J., Barker, Christopher A., Carvajal, Richard D., Wolchok, Jedd D., Chapman, Paul B., Lacouture, Mario E.
Publicado no J Clin Oncol (2014)

Osteonecrosis of the Jaw a New Complication Related to Ipilimumab

Por Owosho, Adepitan A., Scordo, Michael, Yom, SaeHee K., Randazzo, Joseph, Chapman, Paul B., Huryn, Joseph M., Estilo, Cherry L.
Publicado no Oral Oncol (2015)

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAF(V600) mutated malignancies

Por Momtaz, Parisa, Pentsova, Elena, Abdel-Wahab, Omar, Diamond, Eli, Hyman, David, Merghoub, Taha, You, Daoqi, Gasmi, Billel, Viale, Agnes, Chapman, Paul B.
Publicado no Oncotarget (2016)

Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma

Por Yancovitz, Molly, Yoon, Joanne, Mikhail, Maryann, Gai, Weiming, Shapiro, Richard L., Berman, Russell S., Pavlick, Anna C., Chapman, Paul B., Osman, Iman, Polsky, David
Publicado em 2007

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

Por Ku, Geoffrey Y, Yuan, Jianda, Page, David B, Schroeder, Sebastian E A, Panageas, Katherine S, Carvajal, Richard D, Chapman, Paul B, Schwartz, Gary K, Allison, James P, Wolchok, Jedd D
Publicado em 2010

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

Por Solit, David B., Osman, Iman, Polsky, David, Panageas, Katherine S., Daud, Adil, Goydos, James S., Teitcher, Jerrold, Wolchok, Jedd D., Germino, F. Joseph, Krown, Susan E., Coit, Daniel, Rosen, Neal, Chapman, Paul B.
Publicado em 2008

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Por Flaherty, Keith T., Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., O'Dwyer, Peter J., Lee, Richard J., Grippo, Joseph F., Nolop, Keith, Chapman, Paul B.
Publicado em 2010

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T cell activation in vitro, elicit anti-tumor T cell responses comparable to peptide-loaded monocyte-derived d...

Por Romano, Emanuela, Rossi, Marco, Ratzinger, Gudrun, de Cos, Maria-Angeles, Chung, David J., Panageas, Katherine S., Wolchok, Jedd D., Houghton, Alan N., Chapman, Paul B., Heller, Glenn, Yuan, Jianda, Young, James W.
Publicado em 2011

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

Por Callahan, Margaret K., Rampal, Raajit, Harding, James J., Klimek, Virginia M., Chung, Young Rock, Merghoub, Taha, Wolchok, Jedd D., Solit, David B., Rosen, Neal, Abdel-Wahab, Omar, Levine, Ross L., Chapman, Paul B.
Publicado em 2012

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

Por Puzanov, Igor, Amaravadi, Ravi K., McArthur, Grant A., Flaherty, Keith T., Chapman, Paul B., Sosman, Jeffrey A., Ribas, Antoni, Shackleton, Mark, Hwu, Patrick, Chmielowski, Bartosz, Nolop, Keith B., Lin, Paul S., Kim, Kevin B.
Publicado no Eur J Cancer (2015)

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Por Joseph, Eric W., Pratilas, Christine A., Poulikakos, Poulikos I., Tadi, Madhavi, Wang, Weiqing, Taylor, Barry S., Halilovic, Ensar, Persaud, Yogindra, Xing, Feng, Viale, Agnes, Tsai, James, Chapman, Paul B., Bollag, Gideon, Solit, David B., Rosen, Neal
Publicado em 2010